Observational Cohorts Link Highest Plasma Xylitol Quartile to 18-57% Higher MACE Risk
Two large observational cohorts associate higher circulating xylitol with increased cardiovascular events in a dose-dependent manner. The findings are preliminary, un-peer-reviewed, and subject to confounding. Randomized trials measuring hard endpoints are required before clinical or regulatory conclusions can be drawn.
Next steps require prospective intervention trials that randomize participants to xylitol-sweetened versus alternative-sweetened products while tracking platelet function and incident events, plus pharmacokinetic studies quantifying post-prandial excursions after typical dietary exposures. Until such evidence exists, observational dose-response signals alone cannot establish causality or justify label changes.
VITALIS: No FDA or EMA label change or intake limit for xylitol will be issued within 24 months absent publication of at least one RCT reporting >20% relative reduction in MACE with xylitol avoidance.
Sources (3)
- [1]European Society of Cardiology Congress 2026 Late-Breaking Science(https://www.escardio.org/Congresses-Events/ESC-Congress)
- [2]Witkowski et al., European Heart Journal 2024; xylitol-platelet interaction(https://academic.oup.com/eurheartj/article/45/22/2034)
- [3]Mazi et al., Nature Medicine 2023; erythritol cardiovascular outcomes(https://www.nature.com/articles/s41591-023-02223-9)